An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.

Gupta, Rishi; Shipa, Muhammad; Yeoh, Su-Ann; Buck, Pauline; Ehrenstein, Michael R

Gupta, Rishi; Shipa, Muhammad; Yeoh, Su-Ann; Buck, Pauline; Ehrenstein, Michael R.

Gupta R; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
Shipa M; Department of Rheumatology, University College London, London, UK.
Yeoh SA; Department of Rheumatology, University College London, London, UK.
Buck P; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
Ehrenstein MR; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.

Rheumatology (Oxford) ; 60(2): 977-979, 2021 02 01.

Article in English | MEDLINE | ID: covidwho-966901

Subject(s)

Abatacept/administration & dosage; Antibodies, Monoclonal, Humanized/administration & dosage; Antirheumatic Agents/administration & dosage; Arthritis, Rheumatoid/drug therapy; Drug Substitution; Patient Preference; Arthritis, Rheumatoid/physiopathology; COVID-19; Decision Making, Shared; Disease Progression; Humans; Infusions, Intravenous; Injections, Subcutaneous; SARS-CoV-2; Self Administration; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / Patient Preference / Drug Substitution / Antibodies, Monoclonal, Humanized / Abatacept Type of study: Prognostic study Limits: Humans Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2021 Document Type: Article Affiliation country: Rheumatology

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google